1-Year Follow Up Data Shows Bivalirudin Reduces Clinical Events In Heart Attack Patients Undergoing Angioplasty (HORIZONS-AMI Study)

Use of the anticlotting drug bivalirudin results in less complications/clinical events in heart attack patients undergoing angioplasty than does use of the conventional treatment of heparin plus a glycoprotein inhibitor (GPI). The findings of the HORIZON-AMI study are reported in an Article Online First and in an upcoming edition of The Lancet, by Dr Roxana Mehran, Columbia University Medical Center, New York, USA.